REPL Stock Forecast & Price Target

Replimune Group Inc. has demonstrated a significant improvement in the probability of approval for its RP1 + Opdivo treatment in anti-PD-1 failed melanoma patients, increasing from 50% to 85% due to promising trial results indicating a notable overall response rate improvement from 11.5% to 29.8%. The company has extended its cash runway into the first quarter of 2027, supported by strategic financial maneuvers including the drawdown of $35 million from a loan and potential additional funding of up to $120 million tied to post-approval milestones. Moreover, the safety profile of RP1 + Opdivo appears favorable, with a low incidence of severe treatment-related adverse events, further bolstering the case for regulatory approval and enhancing investor confidence.

Replimune Group Inc. reported a net loss of $70.9 million for FY3Q26, which, while slightly better than prior estimates, indicates ongoing financial struggles with substantial R&D and G&A expenses. The company faces significant risks, including the potential inability to generate effective clinical trial data for its lead product RP1, the possibility of additional regulatory hurdles from the FDA, and the overall challenge of achieving regulatory approval. These factors, coupled with the risk of medium- to long-term dilution, contribute to a negative outlook for Replimune Group's stock performance in the near future.